Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia

Landén, Mikael; Grenfeldt, B.; Davidsson, Pia; Stridsberg, Mats; Regland, Björn; Gottfries, Carl‐Gerhard; Blennow, Kaj

doi:10.1016/s0924-977x(98)00042-x

Cited by 31 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 A reduction of chromogranin B levels in cerebrospinal fluid (CSF), as well as chromogranin B-like immunoreactivity in distinct subregions of the hippocampus were reported in patients with SZ. 39,40 Its biological function as potential precursor of active neuropeptide and disease-associated mechanism(s) remain uncharacterized. 41 Given that chromogranins A and B are present in human cerebrospinal fluid at higher concentration than in plasma, and have a role in the biochemistry of the synapses, they may serve as markers for large dense-core synaptic vesicle function and pathology.…”

Section: Synapse and Neurotransmissionmentioning

confidence: 99%

“…41 Given that chromogranins A and B are present in human cerebrospinal fluid at higher concentration than in plasma, and have a role in the biochemistry of the synapses, they may serve as markers for large dense-core synaptic vesicle function and pathology. 39,42 Potential drug effects for the microarray screening of candidate genes were generally discussed previously. 13 Although Landén et al 39 reported no correlation between the levels of the chromogranins and lifetime or recent neuroleptic dose, as well as medicated or drug-free status in SZ, contradictory results were reported in other studies.…”

Section: Synapse and Neurotransmissionmentioning

confidence: 99%

“…39,42 Potential drug effects for the microarray screening of candidate genes were generally discussed previously. 13 Although Landén et al 39 reported no correlation between the levels of the chromogranins and lifetime or recent neuroleptic dose, as well as medicated or drug-free status in SZ, contradictory results were reported in other studies. [43][44][45] The expression of chromogranin A may be significantly influenced by neuroleptic medication, as a reduction of cerebrospinal fluid chromogranin A level was demonstrated in patients with SZ chronically treated with neuroleptic medications.…”

Section: Synapse and Neurotransmissionmentioning

confidence: 99%

See 2 more Smart Citations

An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes

Chu

Liu

2010

J Hum Genet

View full text Add to dashboard Cite

Schizophrenia is a highly complex inheritable disease characterized by numerous genetic susceptibility elements, each contributing a modest increase in risk for the disease. Although numerous linkage or association studies have identified a large set of schizophrenia-associated loci, many are controversial. In addition, only a small portion of these loci overlaps with the large cumulative pool of genes that have shown changes of expression in schizophrenia. Here, we applied a genomic gene-function approach to identify susceptibility loci that show direct effect on gene expression, leading to functional abnormalities in schizophrenia. We carried out an integrated analysis by cross-examination of the literature-based susceptibility loci with the schizophrenia-associated expression gene list obtained from our previous microarray study (Journal of Human Genetics (2009) 54: 665-75) using bioinformatic tools, followed by confirmation of gene expression changes using qPCR. We found nine genes (CHGB, SLC18A2, SLC25A27, ESD, C4A/C4B, TCP1, CHL1 and CTNNA2) demonstrate gene-function correlation involving: synapse and neurotransmission; energy metabolism and defense mechanisms; and molecular chaperone and cytoskeleton. Our findings further support the roles of these genes in genetic influence and functional consequences on the development of schizophrenia. It is interesting to note that four of the nine genes are located on chromosome 6, suggesting a special chromosomal vulnerability in schizophrenia.

show abstract

Section: Synapse and Neurotransmissionmentioning

confidence: 99%

Section: Synapse and Neurotransmissionmentioning

confidence: 99%

Section: Synapse and Neurotransmissionmentioning

confidence: 99%

See 1 more Smart Citation

An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes

Chu

Liu

2010

J Hum Genet

View full text Add to dashboard Cite

show abstract

“…51 It is interesting to note that our finding of decreased CSF levels of SgII in bipolar disorder contrasts with that from a previous study of patients with schizophrenia (unaltered concentrations of SgII). 18 Hypothetically, these contrasting findings might reflect a functional difference in the underlying pathogenesis of schizophrenia and bipolar disorder. However, psychosis was positively associated with SgII in the present study.…”

Section: Discussionmentioning

confidence: 99%

“…13 Altered (mainly reduced) CSF concentrations of different granins have previously been reported in studies of neurologic disorders like Alzheimer disease, 14 multiple sclerosis, 15 amyotrophic lateral sclerosis, 16 frontotemporal dementia 17 and schizophrenia. 18 A role of chromogranins in psychiatric disorders has been further suggested by genetic [19][20][21][22] and postmortem brain studies of patients with schizophrenia. 23,24 Interestingly, in this context, lithium -the treatment of choice to stabilize mood in patients with bipolar disorder -has been reported to enhance expression of granins and secretion of DCGs.…”

Section: Introductionmentioning

confidence: 99%

Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder

Jakobsson

Stridsberg²,

Zetterberg³

et al. 2013

J Psychiatry Neurosci

Self Cite

View full text Add to dashboard Cite

Chromogranin A in the early steps of the neurosecretory pathway

2019

View full text Add to dashboard Cite

Chromogranin A (CgA) is a soluble glycoprotein stored with hormones and neuropeptides in secretory granules (SG) of most (neuro)endocrine cells and neurons. Since its discovery in 1967, many studies have reported its structural characteristics, biological roles, and mechanisms of action. Indeed, CgA is both a precursor of various biologically active peptides and a granulogenic protein regulating the storage and secretion of hormones and neuropeptides. This review emphasizes the findings and theoretical concepts around the CgA‐linked molecular machinery controlling hormone/neuropeptide aggregation and the interaction of CgA‐hormone/neuropeptide aggregates with the trans‐Golgi membrane to allow hormone/neuropeptide targeting and SG biogenesis. We will also discuss the intriguing alteration of CgA expression and secretion in various neurological disorders, which could provide insights to elucidate the molecular mechanisms underlying these pathophysiological conditions.

show abstract

Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia

Cited by 31 publications

References 27 publications

An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes

An integrated genomic analysis of gene-function correlation on schizophrenia susceptibility genes

Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder

Chromogranin A in the early steps of the neurosecretory pathway

Contact Info

Product

Resources

About